These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38745965)

  • 1. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
    Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
    EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
    Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
    J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
    Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
    Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
    Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S
    Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
    J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma.
    Wu J; Bai X; Yu G; Zhang Q; Tian X; Wang Y
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):340. PubMed ID: 38976071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
    Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
    Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
    J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
    Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
    Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J; Yang B; Teng Z; Liu Y; Li D; Qu X
    Front Immunol; 2024; 15():1430196. PubMed ID: 39355238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
    Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
    J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang JX; Chen P; Liu S; Zu QQ; Shi HB; Zhou CG
    J Hepatocell Carcinoma; 2022; 9():265-272. PubMed ID: 35388358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
    Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
    J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.